Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
暂无分享,去创建一个
Melissa A. Basford | J M Pulley | D M Roden | D. Roden | J. Denny | J. Schildcrout | J. Peterson | M. Ritchie | R. Wilke | H. Xu | J. Denny | D. Roden | R. Wilke | D. Crawford | D. Masys | W. Gregg | A. Ramirez | J. Pulley | E. Bowton | J. Cowan | M. Basford | M. Ritchie | J. Peterson | D R Masys | M D Ritchie | D C Crawford | J S Schildcrout | J C Denny | E Bowton | W Gregg | M A Basford | J D Cowan | H Xu | A H Ramirez | J F Peterson | R A Wilke | D. Crawford | M. Basford | Hua Xu
[1] R. Altman,et al. Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.
[2] H. Faruki,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.
[3] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[4] J. Tait,et al. Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.
[5] E. Antman,et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.
[6] Abigail Cohen,et al. Hospitalization costs associated with warfarin‐related bleeding events among older community‐dwelling adults , 2010, Pharmacoepidemiology and drug safety.
[7] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[8] Shashi Amur,et al. Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.
[9] Joshua C Denny,et al. Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records , 2010, Genetics in Medicine.
[10] D. Roden,et al. Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.
[11] D. Hospenthal,et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. , 2006, Military medicine.
[12] C. Chute,et al. Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium , 2011, Science Translational Medicine.
[13] F. Collins,et al. The path to personalized medicine. , 2010, The New England journal of medicine.
[14] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[15] E. Colman,et al. Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.
[16] J. A. Gómez-Capilla,et al. Multi-mutational analysis of fifteen common mutations of the glucose 6-phosphate dehydrogenase gene in the Mediterrranean population. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[17] D. Roden,et al. Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record , 2012, Clinical pharmacology and therapeutics.
[18] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[19] Marc S. Williams,et al. A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing , 2010, PharmacoEconomics (Auckland).
[20] D M Roden,et al. Pharmacogenomics at the Tipping Point: Challenges and Opportunities , 2011, Clinical pharmacology and therapeutics.
[21] W. Newman,et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? , 2010, Pharmacogenomics.
[22] Jerry Avorn,et al. Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation , 2009, Circulation. Cardiovascular quality and outcomes.
[23] Jon Emery,et al. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.
[24] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[25] F. Schmidt. Meta-Analysis , 2008 .
[26] R. Weinshilboum,et al. Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.
[27] Richard L Berg,et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. , 2007, Basic & clinical pharmacology & toxicology.
[28] R. Walensky,et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV , 2008, AIDS.
[29] R. Steinbrook,et al. Opportunities and Challenges for the NIH — An Interview with Francis Collins , 2009 .
[30] J. Horowitz,et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data , 2010, Journal of thrombosis and haemostasis : JTH.
[31] Issam Zineh,et al. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. , 2010, Pharmacogenomics.
[32] F. Ajmar,et al. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. , 1967, The New England journal of medicine.
[33] Francis Collins,et al. Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook. , 2009, The New England journal of medicine.
[34] A. Terzic,et al. Patient-centric clinical pharmacology advances the path to personalized medicine. , 2011, Biomarkers in medicine.
[35] T. Delea,et al. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. , 2010, Clinical breast cancer.
[36] Son Doan,et al. Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..